Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer

Amphiregulin (AREG) is an epidermal growth factor receptor (EGFR) ligand. The aim of this study was to investigate the effects of baseline plasma AREG levels in KRAS, NRAS, and BRAF wild-type metastatic colorectal cancer (CRC) on treatment outcome with palliative first-line cetuximab + FOLFIRI chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sang-A, Park, Hyejoo, Kim, Kui-Jin, Kim, Ji-Won, Sung, Ji Hea, Nam, Milang, Lee, Ju Hyun, Jung, Eun Hee, Suh, Koung Jin, Lee, Ji Yun, Kim, Se Hyun, Lee, Jeong-Ok, Kim, Jin Won, Kim, Yu Jung, Kim, Jee Hyun, Bang, Soo-Mee, Lee, Jong Seok, Lee, Keun-Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664812/
https://www.ncbi.nlm.nih.gov/pubmed/34893673
http://dx.doi.org/10.1038/s41598-021-03197-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664812/
https://www.ncbi.nlm.nih.gov/pubmed/34893673
http://dx.doi.org/10.1038/s41598-021-03197-9

Ejemplares similares